Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update

Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Jung Yong, Suh, Cheolwon, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979644/
https://www.ncbi.nlm.nih.gov/pubmed/27606052
http://dx.doi.org/10.12688/f1000research.8790.1
_version_ 1782447345976213504
author Hong, Jung Yong
Suh, Cheolwon
Kim, Won Seog
author_facet Hong, Jung Yong
Suh, Cheolwon
Kim, Won Seog
author_sort Hong, Jung Yong
collection PubMed
description Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.
format Online
Article
Text
id pubmed-4979644
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-49796442016-09-06 Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update Hong, Jung Yong Suh, Cheolwon Kim, Won Seog F1000Res Review Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL. F1000Research 2016-08-08 /pmc/articles/PMC4979644/ /pubmed/27606052 http://dx.doi.org/10.12688/f1000research.8790.1 Text en Copyright: © 2016 Hong JY et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Hong, Jung Yong
Suh, Cheolwon
Kim, Won Seog
Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update
title Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update
title_full Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update
title_fullStr Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update
title_full_unstemmed Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update
title_short Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update
title_sort evolution of frontline treatment of diffuse large b-cell lymphoma: a brief review and recent update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979644/
https://www.ncbi.nlm.nih.gov/pubmed/27606052
http://dx.doi.org/10.12688/f1000research.8790.1
work_keys_str_mv AT hongjungyong evolutionoffrontlinetreatmentofdiffuselargebcelllymphomaabriefreviewandrecentupdate
AT suhcheolwon evolutionoffrontlinetreatmentofdiffuselargebcelllymphomaabriefreviewandrecentupdate
AT kimwonseog evolutionoffrontlinetreatmentofdiffuselargebcelllymphomaabriefreviewandrecentupdate

Ejemplares similares